Perrigo (PRGO) Other Non-Current Assets (2013 - 2026)
Perrigo (PRGO) posted quarterly Other Non-Current Assets of $264.6 million for Q1 2026, down 12.06% year-over-year from $300.9 million in Q1 2025, and down 2.93% quarter-over-quarter from $272.6 million in Q4 2025.
Perrigo (PRGO) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Other Non-Current Assets for 14 consecutive years, with $264.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 12.06% year-over-year to $264.6 million; the TTM figure through Mar 2026 stood at $264.6 million (down 12.06% YoY), while the FY2025 annual figure was $272.6 million, down 14.44% from the prior year.
- Other Non-Current Assets retreated to $264.6 million in Q1 2026 per PRGO's latest filing, from $272.6 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $541.5 million in Q4 2022 and bottomed at $264.6 million in Q1 2026.
- Historically, Other Non-Current Assets has averaged $341.8 million across 5 years, with a median of $335.2 million in 2023.
- On a YoY basis, Other Non-Current Assets climbed as much as 2183.85% in 2022 and fell as far as 80.44% in 2022.
- Perrigo's Other Non-Current Assets stood at $367.7 million in 2022, then retreated by 8.84% to $335.2 million in 2023, then slipped by 4.95% to $318.6 million in 2024, then retreated by 14.44% to $272.6 million in 2025, then slipped by 2.93% to $264.6 million in 2026.
- Business Quant data shows PRGO's Other Non-Current Assets at $264.6 million in Q1 2026, $272.6 million in Q4 2025, and $280.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Perrigo | 1.94 Bn | 1.54 Bn | 313.90 Mn | 258.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 258.60 Mn |
| Mar 28, 2026 | 264.60 Mn |
| Dec 31, 2025 | 272.60 Mn |
| Sep 27, 2025 | 280.50 Mn |
| Jun 28, 2025 | 301.60 Mn |
| Mar 29, 2025 | 300.90 Mn |
| Dec 31, 2024 | 318.60 Mn |
| Sep 28, 2024 | 299.50 Mn |
| Jun 29, 2024 | 292.30 Mn |
| Mar 30, 2024 | 349.40 Mn |
| Dec 31, 2023 | 335.20 Mn |
| Sep 30, 2023 | 387.30 Mn |
| Jul 1, 2023 | 371.60 Mn |
| Apr 1, 2023 | 342.80 Mn |
| Dec 31, 2022 | 367.70 Mn |
| Oct 1, 2022 | 541.50 Mn |
| Jul 2, 2022 | 408.60 Mn |
| Apr 2, 2022 | 375.70 Mn |
| Dec 31, 2021 | 16.10 Mn |
| Jul 3, 2021 | 2.09 Bn |